Xellia starts sterile injectable production at once vilified U.S. plant

After nearly five years and significant investment, commercial production is again underway at a plant that was once the poster-child of pharma production quality failures. Following a January inspection, the FDA has given its nod of approval for Xellia Pharmaceuticals to start manufacturing at the sterile injectables plant in the Cleveland, Ohio suburb of Bedford. The Copenhagen, Denmark-based Xellia says it will use the greater capacity to scale up its approved pipeline of antiinfectives and to produce injectable drugs on contract. It has more than 200 employees at the plant after investing more than $200 million to revamp it, a spokesman said in an email.